| Product Code: ETC8930776 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Republic of North Macedonia continues to see substantial growth in the import of large molecule drug substances from key countries like the UK, USA, China, Sweden, and Japan. The high Herfindahl-Hirschman Index (HHI) indicates a concentrated market landscape in 2024. The impressive compound annual growth rate (CAGR) of 9.15% from 2020 to 2024, along with a significant growth rate of 10.69% in 2024, underscores the country`s increasing reliance on these top exporting nations for its pharmaceutical needs. This trend reflects a positive outlook for the pharmaceutical industry in North Macedonia.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Republic of Macedonia Large Molecule Drug Substance CDMO Market Overview |
3.1 Republic of Macedonia Country Macro Economic Indicators |
3.2 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Republic of Macedonia Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 Republic of Macedonia Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Republic of Macedonia Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for large molecule drug development services |
4.2.2 Growing outsourcing trend in pharmaceutical industry |
4.2.3 Favorable government regulations supporting CDMOs in Macedonia |
4.3 Market Restraints |
4.3.1 Intense competition from established CDMOs in other regions |
4.3.2 Limited pool of skilled workforce specialized in large molecule drug development |
4.3.3 Regulatory challenges and compliance requirements |
5 Republic of Macedonia Large Molecule Drug Substance CDMO Market Trends |
6 Republic of Macedonia Large Molecule Drug Substance CDMO Market, By Types |
6.1 Republic of Macedonia Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 Republic of Macedonia Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Republic of Macedonia Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Republic of Macedonia Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Republic of Macedonia Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 Republic of Macedonia Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 Republic of Macedonia Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Number of new partnerships and collaborations with pharmaceutical companies |
8.3 Growth in the number of skilled professionals trained in biopharmaceutical manufacturing techniques |
9 Republic of Macedonia Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 Republic of Macedonia Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 Republic of Macedonia Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 Republic of Macedonia Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Republic of Macedonia Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 Republic of Macedonia Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Republic of Macedonia Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |